Skip to content

Christopher Jenks

Independent Researcher, Fair Oaks, CA, 95628, USA.

2 papers in the library · 22 citations · publishing 2020

Papers

An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers

Archives of Clinical Psychiatry (São Paulo) April 1, 2020 José Carlos Bouso, I. Fornís, Mireia Ventura et al. 15 citations

The purity of iboga products sold online and by treatment providers is highly variable. Analysis of 16 samples—including root bark, total alkaloids, purified total alkaloids, and ibogaine hydrochloride—found ibogaine content ranging from 0.6% to 11.2% in root bark, 8.2% to 32.9% in total alkaloid products, 73.7% in one purified sample, and 61.5% to 73.4% in ibogaine hydrochloride samples. One sample contained no iboga alkaloids. Almost all samples also contained other alkaloids and unknown substances. The variability poses risks for correct dosing and potential adverse reactions or interactions.

Quantitative Evaluation of a Mexican and a Ghanaian Tabernaemontana Species as Alternatives to Voacanga africana for the Production of Antiaddictive Ibogan Type Alkaloids.

Chemistry & biodiversity May 1, 2020 Felix Krengel, Jonathan Dickinson, Christopher Jenks et al. 7 citations

Gas chromatography-mass spectrometry (GC/MS) compared the alkaloid profiles of bark and leaf from one Mexican species (Tabernaemontana arborea) and one African species (T. crassa) with the primary commercial sources of semisynthetic ibogaine, Voacanga africana root and stem bark. The qualitative and quantitative similarities between T. arborea and V. africana barks support previous reports that T. arborea is a promising alternative source of voacangine and ibogaine. The results also suggest that T. crassa could be used to produce conopharyngine and ibogaline, two compounds with the same basic skeletal structure and possibly similar antiaddictive properties as ibogaine.